ArticleDermatology practical & conceptual2026
Efficacy of Oral Cicaglocal for Wound Healing and Pruritus Alleviation in Patients with Epidermolysis Bullosa: A Single-Arm Clinical Trial.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEpidermolysis bullosa (EB) is a rare dermatosis causing mucocutaneous fragility, which can culminate in secondary afflictions such as contractures. This disease can adversely impact the lives of sufferers with pruritus.
objectiveThis study was conducted to assess the effects of Cicaglocal in improving wound repair and pruritus intensity in EB patients.
methodThis single-arm non-randomized trial was carried out in 2024 on 12 EB patients. The recruited patients administered one capsule of Cicaglocal daily for 28 days. Intensities of pruritus and pain were measured with the visual analogue scale. Also, patients' improvement was assessed utilizing clinical global impression of improvement and patient global impression of improvement. Furthermore, dimensions of ulcers were measured. These examinations were implemented on the first day, prior to the start of taking Cicaglocal, and after four weeks. We used the IBM ™ SPSS Statistics application (version 20.0) for statistical analyses.
resultsPatients included six females and six males of Persian ethnicity, with an average age of 20.17 ± 11.99 years. Despite no remarkable change in the count and length of the ulcers, the width of wounds (median width: 9.5 mm to 4.5 mm, P=0.042) and magnitude of pruritus (median: 8.5 to 4.5 mm, P=0.026) exhibited a statistically significant decrease after four weeks of treatment. Moreover, three and two patients developed gastritis and esophagitis, respectively.
conclusionCicaglocal was a relatively efficient medication for relieving pruritus and enhancing wound healing in EB patients. However, we highly recommend more studies on these issues.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.